P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

October 2012

Features

Editorial

Synthetic Cathinones (‘Bath Salts’)

Legal and Health Care Challenges

The growing abuse of toxic stimulants known as “bath salts” can cause psychosis and possibly death. Raising awareness of the dangers through patient counseling and community outreach programs will be important—especially efforts aimed at young people.
Jennifer A. Gershman, PharmD, CPh; and Andrea D. Fass, PharmD

State Cutbacks to Medicaid May Hit Hospitals Hard

New Federal Reductions Might Compound the Stress

Hospitals, low-income families, and disabled individuals who rely on Medicaid funding will be struggling financially if the government reduces its outlays to the states by $800 billion over the next 10 years in order to reduce the federal deficit.
Stephen Barlas

Pregabalin and Simvastatin

First Report of a Case of Rhabdomyolysis

A 70-year-old man with a history of fibromyalgia, type-2 diabetes mellitus, hypercholesterolemia, and chronic low back pain presented to the emergency department with altered mental status, limb weakness, twitching, and slurred speech. The authors sought to determine whether his rhabdomyolysis resulted from an adverse reaction associated with pregabalin and simvastatin.
Michele B. Kaufman, PharmD; and Mary Choy, PharmD

The Nanomedicine Revolution, Part 2

Current and Future Clinical Applications

Although many nanotherapeutic and nanodiagnostic agents are in use and have the potential to improve health care, many barriers have impeded the development and availability of these products. Despite these impediments, it is expected that nanomaterials will become an integral part of mainstream medicine.
C. Lee Ventola, MS

European Society of Cardiology Congress 2012

Topics include antiplatelet drugs for acute coronary syndrome, renal denervation for hypertension, contrast-induced nephropathy, “e-cigarettes,” and resistant hypertension.
Walter Alexander

Departments

Medication Errors

‘Inattentional Blindness’

What Captures Your Attention?

Many mistakes can result from ‘inattentional blindness.’
Matthew Grissinger, RPh, FASCP

Prescription: Washington

‘Gray Market’ Not Such a Gray Area Anymore

Why Hospitals Are Paying Exorbitant Drug Prices

Hospitals are paying exorbitant prices for drugs because of an insidious “gray market” pipeline.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Truvada for HIV prevention, Xtandi for metastatic castration-resistant prostate cancer, and Marqibo, a vincristine liposome injection for acute myelogenous leukemia
Marvin M. Goldenberg, PhD, RPh, MS

Drug Forecast

Ticagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome

RaeAnne Fuller, PharmD; and Benjamin Chavez, PharmD, BCPP